Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron Pharmaceuticals Inc stock Dividend Yield % is close to 2-year high.
During the past 12 months, Regeneron Pharmaceuticals's average Dividends Per Share Growth Rate was 306.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Regeneron Pharmaceuticals (LTS:0R2M) Dividends per Share Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
Regeneron Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as
During the past 13 years, the highest Dividend Payout Ratio of Regeneron Pharmaceuticals was 0.08. The lowest was 0.08. And the median was 0.08.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Regeneron Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 0.940000
2026-05-20
2026-05-20
2026-06-04
Cash Dividend
quarterly
USD:USD 1.000000
USD 0.940000
2026-02-20
2026-02-20
2026-03-05
Cash Dividend
quarterly
USD:USD 1.000000
USD 0.880000
2025-11-20
2025-11-20
2025-12-05
Cash Dividend
quarterly
USD:USD 1.000000
USD 0.880000
2025-08-18
2025-08-18
2025-09-03
Cash Dividend
quarterly
USD:USD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Regeneron Pharmaceuticals's Dividend Yield (%) for Today is calculated as
Current Share Price is $676.38.
Regeneron Pharmaceuticals's Dividends per Share for the trailing twelve months (TTM) ended in Today is $3.64.
During the past 13 years, the highest Dividend Yield of Regeneron Pharmaceuticals was 0.59%. The lowest was 0.15%. And the median was 0.41%.
Good Sign:
Regeneron Pharmaceuticals Inc stock Dividend Yield % is close to 2-year high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals Dividends per Share Related Terms
Regeneron Pharmaceuticals Dividends per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals Dividends per Share Chart
LTS:0R2M vs ALNY, RVMD, ONC: Dividends per Share Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Dividend Yield % falls into.
Regeneron Pharmaceuticals (LTS:0R2M) has a Dividends per Share of $3.58 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Dividends per Share too high?
Regeneron Pharmaceuticals' current Dividends per Share is $3.58. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Dividends per Share compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Dividends per Share of $3.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Dividends per Share is $3.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Modestly Undervalued. The stock's GF Value™ is $910.39, compared to a current price of $676.38 — trading 25.7% below its estimated fair value. The current Dividends per Share is $3.58. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current Dividends per Share is $3.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of $676.38 is trading 25.7% below its estimated GF Value™ of $910.39.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for LTS:0R2M:
Dividends per Share: $3.58
GF Value™: $910.39 vs. price of $676.38 (25.7% below fair value)
No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score
Get the complete analysis for LTS:0R2M
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2M has been successfully added to your 
